Lofexidine, an {alpha}2-receptor agonist for opioid detoxification

Area of Science:

• Pharmacology
• Toxicology
• Pharmacokinetics

Background:

• Opioid withdrawal presents significant challenges in addiction treatment.
• Current detoxification methods often involve opioid receptor agonists.
• There is a need for effective non-opioid alternatives.

Purpose of the Study:

• To review the pharmacology, toxicology, pharmacokinetics, efficacy, and safety of lofexidine for opioid detoxification.
• To evaluate lofexidine's potential as a non-opioid treatment for opioid withdrawal.

Main Methods:

• Literature search of MEDLINE, EMBASE, International Pharmaceutical Abstracts, and Cochrane Library (1950-2009).
• Inclusion of English-language studies on animal and human data, and clinical trials comparing lofexidine to placebo or active controls.
• Review of nine clinical studies involving 354 patients.

Main Results:

• Lofexidine, an alpha-2 agonist, reduces sympathetic outflow, alleviating many opioid withdrawal symptoms.
• Clinical trials suggest lofexidine is effective for opioid detoxification, comparable to opioid receptor agonists.
• Common adverse events include insomnia and aching; lofexidine may have a better safety profile than clonidine.

Conclusions:

• Lofexidine demonstrates potential as a novel non-opioid agent for opioid detoxification.
• If approved, it would be the first non-opioid medication for this indication.
• Further large-scale studies are required to establish optimal dosage and safety.